LANTHEUS HOLDINGS INC (NASDAQ:LNTH) Shares Plunge 20.8% After Q2 2025 Earnings Miss and Weak Guidance

LANTHEUS HOLDINGS INC (NASDAQ:LNTH) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The market reaction was swift and severe, with shares plummeting approximately 20.8% in pre-market trading.

Key Financial Highlights vs. Estimates

• Revenue: Reported $378 million, down 4.1% year-over-year and falling short of the $396.9 million consensus estimate.
• EPS (Non-GAAP): Came in at $1.57, below the estimated $1.71, marking a 6.3% miss.
• Full-Year Guidance: The company projected full-year revenue of $1.49 billion at the midpoint, which is 5% below analysts' expectations of $1.6 billion.

The revenue decline and weaker-than-expected guidance suggest potential headwinds in demand or operational execution. The significant pre-market drop reflects investor disappointment, particularly given the company’s recent struggles—shares were already down nearly 12% over the past month before this earnings release.

Business and Pipeline Updates

While the financials disappointed, Lantheus did announce some positive regulatory progress:

• FDA NDA Acceptance: The U.S. Food and Drug Administration (FDA) accepted a New Drug Application (NDA) for an improved formulation of its PSMA PET imaging agent, PYLARIFY. The new version aims to increase batch sizes by ~50%, potentially improving supply reliability. The PDUFA date is set for March 6, 2026.

This development could strengthen Lantheus’ position in prostate cancer diagnostics, but the market’s focus remains squarely on the near-term financial underperformance.

Market Reaction and Investor Sentiment

The sharp decline in LNTH’s stock price underscores heightened sensitivity to earnings misses in the current market environment. Key factors driving the sell-off include:

• Revenue Contraction: The year-over-year decline raises concerns about growth sustainability.
• Guidance Cut: The downward revision for full-year revenue suggests management sees ongoing challenges.
• Margin Pressures: The EPS miss indicates potential cost inflation or pricing pressures.

For a deeper dive into Lantheus’ earnings history and future estimates, review the earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.